Every 10-Q that Cellectar Biosciences INC NEW (CLRB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CLRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLRB filings page.
Cellectar Biosciences, Inc. reported a net loss of $6.9M for the quarter and $12.6M for the six months ended June 30, 2026, similar to the prior year, as it continues late‑stage development of its radioconjugate cancer therapies. Operating expenses were $7.2M for the quarter, driven by $4.6M in research and development and $2.6M in general and administrative costs.
Cash and cash equivalents increased to $34.0M from $13.2M at year‑end 2025, primarily from a May 2026 registered direct offering and concurrent private placement providing $35.0M gross ($31.7M net) upfront and up to $105M in milestone-based securities. The company used $10.9M of cash in operating activities in the first half. Management discloses that, despite this financing, there is substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 without additional capital or strategic actions. At June 30, 2026, stockholders’ equity was $29.9M and 8,252,108 common shares were outstanding.
Cellectar Biosciences reported a Q1 2026 net loss of $5.65M, narrower than $6.60M a year earlier, as operating expenses fell to $5.79M. Cash and cash equivalents were $8.35M versus $13.20M at December 31, 2025, with operating activities using $4.85M of cash in the quarter.
The company remains a pre‑revenue, late‑stage oncology biotech with an accumulated deficit of about $275M and substantial reliance on external financing. Management disclosed substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 without additional actions, despite approximately $37M of liquidity as of the financial statement issuance date.
Clinically, Cellectar highlighted strong follow‑up data from its CLOVER WaM trial in relapsed or refractory Waldenstrom’s macroglobulinemia, including an overall response rate of 83.6% and major response rate of 61.8%, and it is preparing a Phase 3 confirmatory study supported by a financing that includes up to $105M in milestone‑based securities.
Cellectar Biosciences reported a narrower quarterly loss and lower expenses while highlighting liquidity risks. For the three months ended September 30, 2025, net loss was $4.44 million, down from $14.66 million a year ago, as operating expenses fell to $4.85 million from $13.33 million. For the nine months, net loss was $16.50 million versus $42.23 million in 2024.
Cash and cash equivalents were $12.55 million at September 30, 2025. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern and estimated available liquidity of approximately $15.6 million as of the issuance date, with runway potentially extending beyond the third quarter of 2026 if actions are taken.
Financing activity included a $6.9 million underwritten offering on July 2, 2025 and approximately $2.5 million of gross proceeds from warrant exercises on June 6, 2025. A 1‑for‑30 reverse stock split became effective on June 24, 2025. Shares outstanding were 3,192,040 as of September 30, 2025, and 4,240,134 as of November 10, 2025. The FDA granted Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory Waldenström macroglobulinemia on June 4, 2025.
Cellectar Biosciences reports a mixed quarter: clinical progress on its lead radioconjugate and significant financial strain. Total assets declined to $13.7 million from $25.5 million, driven by a fall in cash and cash equivalents to $11.04 million from $23.29 million. The company recorded a net loss of $12.05 million for the six months and has an accumulated deficit of approximately $259.4 million. Operating expenses for the six months totaled $12.44 million, composed of research and development of $5.82 million and general and administrative of $6.62 million.
Operationally, Cellectar received Breakthrough Therapy Designation for iopofosine I-131 in relapsed/refractory Waldenstrom macroglobulinemia and reported strong CLOVER WaM results: a major response rate of 58.2% and an overall response rate of 83.6%. Development programs CLR 125 and CLR 225 are positioned for Phase 1 trials in 2025 but are explicitly conditioned on obtaining additional financing. Management discloses substantial doubt about going concern, with available liquidity near $15 million and runway described as limited absent further financing; planned actions include sales of equity/debt, strategic transactions, and cost savings. A July 2, 2025 underwritten offering raised approximately $6.9 million gross as a subsequent event.